Related Experiment Videos

[Complement regulatory proteins CR 1, MCP, DAF, and MACIF levels in patients with Behçet's disease]

T Kure1, M Kogure

  • 1Department of Ophthalmology, Tokyo Women's Medical College, Japan.

Insights

Patients with Behçet's disease exhibit reduced complement regulatory protein function before ocular attacks. This may be compensated by excessive complement production, impacting disease progression.

Area of Science:

  • Immunology
  • Rheumatology

Background:

  • Serum complement levels are critically low in Behçet's disease patients preceding ocular attacks.
  • Elevated anaphylatoxins (C3a, C5a) correlate negatively with complement component 50 (CH50) levels before ocular attacks.

Purpose of the Study:

  • To investigate the role of complement regulatory proteins in Behçet's disease.
  • To understand the interplay between complement activation and regulation in disease pathogenesis.

Main Methods:

  • Evaluation of complement regulatory proteins, including C3b/C4b receptor (CR1), membrane cofactor protein (MCP), decay accelerating factor (DAF), and membrane attack complex inhibition factor (MACIF).
  • Comparison of CH50 and alternative pathway CH50 (ACH50) levels between patients and controls.

Main Results:

  • Reduced levels of CR1 and MCP, and a diminished tendency for DAF and MACIF function were observed.
  • Despite regulatory protein deficiencies, mean CH50 and ACH50 levels were significantly higher in patients than controls.

Conclusions:

  • The function of complement regulatory proteins appears globally decreased in Behçet's disease.
  • Excessive complement production may be a compensatory mechanism for impaired regulation, potentially contributing to disease activity.

Related Concept Videos